Themis Medicare reported a significant turnaround in profitability for the first quarter of FY27, posting a standalone net profit of ₹287.4 lakh for the period ended June 30, 2026. This compares to a net loss of ₹153.7 lakh in the same quarter of the previous fiscal year. The consolidated net profit attributable to equity holders was ₹246.1 lakh, up from a loss of ₹142.2 lakh in Q1FY26.

The profit surge was not operational but stemmed from a one-time exceptional item. The company recorded a profit of ₹996.7 lakh (standalone) and ₹929.5 lakh (consolidated) following the sale of 2,497,190 equity shares in its associate, Gujarat Themis Biosyn Limited, for a consideration of ₹100 crore. Without this gain, the standalone operations incurred a loss before tax of ₹569.4 lakh.

Financial Performance

Revenue from operations declined during the quarter, reflecting softness in the core pharmaceutical business. Standalone revenue stood at ₹869.6 lakh, down 10.9% year-on-year from ₹975.8 lakh in Q1FY26. On a consolidated basis, revenue remained identical at ₹869.6 lakh.

Operating expenses increased significantly, with total expenses rising to ₹1,449.0 lakh in the standalone results, compared to ₹1,126.8 lakh in the prior year period. Other expenses specifically jumped to ₹592.1 lakh from ₹304.1 lakh year-on-year, contributing to the operational loss despite the revenue contraction being modest.

What the Numbers Show

The financial data reveals a stark divergence between operational performance and bottom-line results. While the company turned profitable on paper, the core business widened its operating loss. The standalone loss before exceptional items and tax expanded to ₹569.4 lakh from ₹139.2 lakh in Q1FY26. This indicates that the profit figure is entirely dependent on non-recurring capital gains rather than improvements in the pharmaceutical segment's efficiency or sales volume.

Key Managerial Personnel Changes

Alongside the financial results, the Board of Directors approved changes in key managerial personnel effective August 13, 2026. Mr. Nagraj Mogaveera resigned as Interim Company Secretary and Compliance Officer to transition into the role of Deputy Manager – Secretarial Department within the company.

Mr. Suresh Savaliya was appointed as the new Company Secretary, Compliance Officer, and Key Managerial Personnel. A qualified Company Secretary and member of the Institute of Company Secretaries of India (ICSI), Mr. Savaliya brings 23 years of post-qualification experience. He previously served with Reliance Industries Limited and the Essel Group, handling corporate governance, SEBI compliances, and board matters.

Auditor Review

Krishna & Co., Chartered Accountants, conducted the limited review of the unaudited standalone and consolidated financial results. The auditors stated that nothing came to their attention to cause them to believe the statements did not disclose the information required under Regulation 33 of the SEBI Listing Regulations or contained material misstatements. The audit report also highlighted the pending RBI approval for writing off investments in the struck-off UK subsidiary, Carpo Medicals Limited.

Themis Medicare reported a consolidated net loss of ₹569 million for the first quarter, marking an improvement against the ₹139 million loss recorded in the corresponding period last year. While the headline loss narrowed significantly year-on-year, the operational performance showed pressure, with the EBITDA loss widening to ₹524 million from ₹101 million in the prior year’s quarter.

The company’s bottom line was heavily influenced by non-operational gains. Themis Medicare recorded a ₹929 million profit on the sale of shares during the quarter. This substantial one-time gain played a critical role in mitigating the operational losses and contributing to the narrower net loss figure compared to the previous year.

Operational Metrics

The divergence between the net loss and the EBITDA loss highlights the impact of other income on the company’s financial results for the quarter.

What the Numbers Show

The financial data reveals a significant dependency on non-operational items for profitability in this quarter. With an EBITDA loss of ₹524 million and a net loss of ₹569 million, the difference is largely accounted for by the ₹929 million gain from share sales. This indicates that without the capital gains from the share sale, the net loss would have been substantially higher, underscoring that the improvement in the net loss figure was driven by exceptional items rather than core operational efficiency.